Glenmark Has Launched A COVID-19 Medicine Called FabiFlu To Treat Mild To Moderate Cases

This Is A Representative Image

India has been reporting a high number of COVID-19 cases every day and research for a vaccine is still on, but, no one knows how much time it might take for it to be available in the market. However, Glenmark Pharmaceuticals, an Indian company, has recently launched an antiviral drug to treat mild to moderate cases in India, and this might be a breakthrough medicine that can help save a million lives. 

Need Of The Hour | The antiviral drug called Favipiravir will be available as a 200 mg tablet at an MRP of Rs 3,500 for a strip of 34 tablets. Available under the brand name FabiFlu, it is the first favipiravir approved medication for the treatment of COVID-19 in India. This prescription based medication has a recommended dose of 1,800 mg twice daily on day one and 800 mg twice daily up to 14 days.

Glenmark will be able to provide this antiviral drug to about 82,500 patients in the 1st month and will be available in both hospitals and retail chains. The availability of this effective treatment will help ease the pressure on the hospitals and save the patients with co-morbid conditions like diabetes and heart disease. This drug will reduce the viral load within 4 days and provides faster improvement.

The clinical research of Favipiravir has shown an improvement of up to 88% in mild and moderate patients. Along with Favipiravir, two more drugs named Covifor and Cipremi are at the approval stage, but the details are not out yet. 

We’re hoping this medicine shows positive results, but remember that the fight is still on, so follow the precautions and stay safe!

Sourced Via Financial Express